Surgical Outcome After Pancreatoduodenectomy for Duodenal Adenocarcinoma Compared with Other Periampullary Cancers: A Nationwide Audit Study.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
12
05
2022
accepted:
04
10
2022
pubmed:
20
12
2022
medline:
23
3
2023
entrez:
19
12
2022
Statut:
ppublish
Résumé
Surgical outcome after pancreatoduodenectomy for duodenal adenocarcinoma could differ from pancreatoduodenectomy for other cancers, but large multicenter series are lacking. This study aimed to determine surgical outcome in patients after pancreatoduodenectomy for duodenal adenocarcinoma, compared with other periampullary cancers, in a nationwide multicenter cohort. After pancreatoduodenectomy for cancer between 2014 and 2019, consecutive patients were included from the nationwide, mandatory Dutch Pancreatic Cancer Audit. Patients were stratified by diagnosis. Baseline, treatment characteristics, and postoperative outcome were compared between groups. The association between diagnosis and major complications (Clavien-Dindo grade III or higher) was assessed via multivariable regression analysis. Overall, 3113 patients, after pancreatoduodenectomy for cancer, were included in this study: 264 (8.5%) patients with duodenal adenocarcinomas and 2849 (91.5%) with other cancers. After pancreatoduodenectomy for duodenal adenocarcinoma, patients had higher rates of major complications (42.8% vs. 28.6%; p < 0.001), postoperative pancreatic fistula (International Study Group of Pancreatic Surgery [ISGPS] grade B/C; 23.1% vs. 13.4%; p < 0.001), complication-related intensive care admission (14.3% vs. 10.3%; p = 0.046), re-interventions (39.8% vs. 26.6%; p < 0.001), in-hospital mortality (5.7% vs. 3.1%; p = 0.025), and longer hospital stay (15 days vs. 11 days; p < 0.001) compared with pancreatoduodenectomy for other cancers. In multivariable analysis, duodenal adenocarcinoma was independently associated with major complications (odds ratio 1.14, 95% confidence interval 1.03-1.27; p = 0.011). Pancreatoduodenectomy for duodenal adenocarcinoma is associated with higher rates of major complications, pancreatic fistula, re-interventions, and in-hospital mortality compared with patients undergoing pancreatoduodenectomy for other cancers. These findings should be considered in patient counseling and postoperative management.
Sections du résumé
BACKGROUND
BACKGROUND
Surgical outcome after pancreatoduodenectomy for duodenal adenocarcinoma could differ from pancreatoduodenectomy for other cancers, but large multicenter series are lacking. This study aimed to determine surgical outcome in patients after pancreatoduodenectomy for duodenal adenocarcinoma, compared with other periampullary cancers, in a nationwide multicenter cohort.
METHODS
METHODS
After pancreatoduodenectomy for cancer between 2014 and 2019, consecutive patients were included from the nationwide, mandatory Dutch Pancreatic Cancer Audit. Patients were stratified by diagnosis. Baseline, treatment characteristics, and postoperative outcome were compared between groups. The association between diagnosis and major complications (Clavien-Dindo grade III or higher) was assessed via multivariable regression analysis.
RESULTS
RESULTS
Overall, 3113 patients, after pancreatoduodenectomy for cancer, were included in this study: 264 (8.5%) patients with duodenal adenocarcinomas and 2849 (91.5%) with other cancers. After pancreatoduodenectomy for duodenal adenocarcinoma, patients had higher rates of major complications (42.8% vs. 28.6%; p < 0.001), postoperative pancreatic fistula (International Study Group of Pancreatic Surgery [ISGPS] grade B/C; 23.1% vs. 13.4%; p < 0.001), complication-related intensive care admission (14.3% vs. 10.3%; p = 0.046), re-interventions (39.8% vs. 26.6%; p < 0.001), in-hospital mortality (5.7% vs. 3.1%; p = 0.025), and longer hospital stay (15 days vs. 11 days; p < 0.001) compared with pancreatoduodenectomy for other cancers. In multivariable analysis, duodenal adenocarcinoma was independently associated with major complications (odds ratio 1.14, 95% confidence interval 1.03-1.27; p = 0.011).
CONCLUSION
CONCLUSIONS
Pancreatoduodenectomy for duodenal adenocarcinoma is associated with higher rates of major complications, pancreatic fistula, re-interventions, and in-hospital mortality compared with patients undergoing pancreatoduodenectomy for other cancers. These findings should be considered in patient counseling and postoperative management.
Identifiants
pubmed: 36536196
doi: 10.1245/s10434-022-12701-y
pii: 10.1245/s10434-022-12701-y
pmc: PMC10027630
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2448-2455Informations de copyright
© 2022. The Author(s).
Références
Surgery. 2011 May;149(5):680-8
pubmed: 21316725
Am Soc Clin Oncol Educ Book. 2014;:112-5
pubmed: 24857067
HPB (Oxford). 2018 Aug;20(8):759-767
pubmed: 29571615
Ann Surg. 2021 Feb 1;273(2):334-340
pubmed: 30829699
Eur J Surg Oncol. 2003 Oct;29(8):634-43
pubmed: 14511609
Ann Surg. 2009 Jan;249(1):63-71
pubmed: 19106677
J Clin Med. 2020 Aug 07;9(8):
pubmed: 32784559
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
HPB (Oxford). 2017 Oct;19(10):919-926
pubmed: 28754367
Ann Surg. 2019 May;269(5):937-943
pubmed: 29240007
Pancreas. 2015 Jan;44(1):41-52
pubmed: 25232714
Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2
pubmed: 10843358
Pancreatology. 2020 Mar;20(2):158-168
pubmed: 31980352
Korean J Hepatobiliary Pancreat Surg. 2016 Feb;20(1):23-31
pubmed: 26925147
Am J Gastroenterol. 2005 Mar;100(3):703-10
pubmed: 15743371
Surgeon. 2017 Oct;15(5):251-258
pubmed: 26711559
HPB (Oxford). 2014 Jan;16(1):83-90
pubmed: 23472829
Eur J Gastroenterol Hepatol. 2016 Dec;28(12):1388-1393
pubmed: 27603299
Medicine (Baltimore). 2017 May;96(19):e6858
pubmed: 28489778
J Gastrointest Surg. 2008 Feb;12(2):270-8
pubmed: 18060467
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
ANZ J Surg. 2014 Dec;84(12):970-5
pubmed: 23656271
Surgery. 2021 Feb;169(2):396-402
pubmed: 32868111
J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565
pubmed: 12691930
Langenbecks Arch Surg. 2022 Feb;407(1):167-173
pubmed: 34471952
Br J Surg. 2012 Mar;99(3):404-10
pubmed: 22237731
Ann Surg Oncol. 2018 Sep;25(9):2681-2692
pubmed: 29946997
HPB (Oxford). 2021 Sep;23(9):1321-1331
pubmed: 34099372
J Surg Oncol. 2019 Mar;119(3):303-317
pubmed: 30561818
Ann Surg. 2019 Aug;270(2):211-218
pubmed: 30829701
Trials. 2020 May 7;21(1):389
pubmed: 32381031
ANZ J Surg. 2018 Mar;88(3):E157-E161
pubmed: 28122405
Surgery. 2007 Jul;142(1):20-5
pubmed: 17629996
World J Surg. 1999 Jun;23(6):584-8
pubmed: 10227928
Ann Surg. 2011 May;253(5):879-85
pubmed: 21368658
J Cancer Res Ther. 2019;15(4):857-863
pubmed: 31436243
J Surg Oncol. 2017 Oct;116(5):617-622
pubmed: 28767125
Acta Chir Belg. 2018 Dec;118(6):341-347
pubmed: 30203717
Perioper Med (Lond). 2021 Feb 17;10(1):5
pubmed: 33593437